日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Sino Biopharm targets 30 innovative products by 2027

By Zhou Wenting in Shanghai | chinadaily.com.cn | Updated: 2025-03-21 14:23
Share
Share - WeChat

Sino Biopharmaceutical Limited, or Sino Biopharm, expects to have approximately five innovative products approved in China each year, bringing the total of its innovative products to at least 30 by 2027, the company announced at a conference on Thursday, where it released its 2024 annual results.

Such continuous innovation efforts demonstrate the company's commitment to meeting patients' clinical needs and contributing to the Healthy China initiative, said Theresa Tse, chairwoman of Sino Biopharm.

The report showed that the Hong Kong-listed company's dedication to innovation has paid off, with its 2024 operating revenue and net profit both achieving double-digit growth. The company reported a total revenue of 28.87 billion yuan ($3.98 billion), representing a 10.2 percent year-on-year increase, while adjusted net profit attributable to shareholders reached 3.46 billion yuan, a 33.5 percent surge.

For the first time, the company also achieved over 10-billion-yuan revenue from its innovative products last year, reaching 12.06 billion yuan, a 21.9 percent year-on-year growth, which accounts for 41.8 percent of the company's total revenue.

"Our relentless focus on innovation over the past decade has led to the establishment of innovative research and development platforms for dual antibodies and ADC (antibody-drug conjugate) drugs among others, resulting in a steady stream of innovative products," said Tse.

The number of innovative products by Sino Biopharm increased from three in 2018 to 17 by the end of 2024, according to the report. Last year alone, the company saw four first-class innovative medicines approved for market, making it the pharmaceutical enterprise with the largest number of such approvals in the year.

Looking ahead, Sino Biopharm anticipates the launch of several blockbuster products for treatment of lung cancer, chronic obstructive pulmonary disease, breast cancer, and others within the next three years.

The company also said that it has strategically positioned itself in the realm of artificial intelligence through collaborations, investments and localized applications. It plans to intensify its investments in AI, expanding its application across R&D, production, sales and functional management to propel corporate development and lead industry innovation upgrades.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 69av.com| 五月激情婷婷六月 | 偷拍—91porny九色 | 天天操夜夜爽 | 欧美日韩一区二区三区高清不卡 | 超级碰碰碰视频视频在线视频 | 欧美日韩黄 | 免费人成在线播放 | jizzjizzjizz亚洲18 | 成人精品福利 | 日韩有码一区二区三区 | 午夜亚洲国产成人不卡在线 | 久青草影视 | 精品一区二区日本高清 | 天天操操 | 亚洲黄区 | 精品国产一区在线观看 | 久久99深爱久久99精品 | 夜夜爽夜夜叫夜夜高潮漏水 | 午夜国产| 欧美精品综合一区二区三区 | 国产亚洲精品精品国产亚洲综合 | 国产精品久久久久免费视频 | 国产精品99久久久久久久女警 | 国产一区二区在线免费观看 | 欧美阿v天堂视频在99线 | 久久久久久久综合日本亚洲 | 精品久久久久一区 | 天堂成人 | 日韩在线观看中文 | 天天做天天添婷婷我也去 | 四虎网站在线观看 | 波多野吉衣一区二区三区四区 | 2021国产精品成人免费视频 | 99久久99热久久精品免费看 | 欧美日韩一区二区在线观看视频 | 久久免费看| 曰韩在线视频 | 国产精品亚洲第一 | 亚洲午夜在线视频 | 国产一区二区欧美 |